Showing results (31-40 of 116) with videos related to

Sort By:
Pageof 12
Blood Reviews|July 6, 2023
Primary and secondary immune thrombocytopenia (ITP): Time for a rethinkTomás José González-López, Drew Provan, Abelardo Bárez, et al.
Therapeutic Advances in Hematology|August 26, 2021
Addition of chemotherapy to nivolumab after PD-1 inhibitor failure as bridge to allogeneic stem cell transplantation in classical Hodgkin's lymphoma: report on three cases and literature reviewSamuel Romero, Aitana Balaguer-Roselló, Juan Montoro, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 17, 2004
Blastoschizomyces capitatus infection in patients with leukemia: report of 26 casesRodrigo Martino, Miguel Salavert, Rocío Parody, et al.
Leukemia & Lymphoma|December 11, 2007
Characteristics of and risk factors for pneumonia in patients with hematological malignancies developing fever after autologous blood stem cell transplantationNoemí Puig, Javier De La Rubia, Isidro Jarque, et al.
Medicina Clinica|January 20, 2012
[Guidelines for diagnosis, treatment and monitoring of primary immune thrombocytopenia]Miguel Ángel Sanz, Vicente Vicente García, Antonio Fernández, et al.
Annals of Hematology|June 8, 2010
Rituximab is an effective and safe therapeutic alternative in adults with refractory and severe autoimmune hemolytic anemiaFrancisco Javier Peñalver, Alberto Alvarez-Larrán, Jose Luis Díez-Martin, et al.
Haematologica|July 6, 2014
Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantationCarlos Vallejo, Montserrat Batlle, Lourdes Vázquez, et al.
Medicina Clinica|February 21, 2016
[Spanish consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria]Ana Villegas, Beatriz Arrizabalaga, Santiago Bonanad, et al.
Critical Care (London, England)|January 1, 2014
Survival of hematological patients after discharge from the intensive care unit: a prospective observational studyTeresa Bernal, Estefanía V Pardavila, Juan Bonastre, et al.
Blood Advances|September 4, 2020
Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopeniaTadeusz Robak, Maciej Kaźmierczak, Isidro Jarque, et al.
Pageof 12